Literature DB >> 3100014

Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particles. Clinical trials.

A Hagiwara, T Takahashi, R Lee, T Ueda, M Takeda, T Itoh.   

Abstract

A new drug dosage form comprising activated carbon particles adsorbing mitomycin C (MMC-CH) is designed to slowly release its components, and has affinity for the tumor surface and lymph nodes and a tendency to stay long in the local portion. The therapeutic index of MMC-CH in experimental carcinomatous peritonitis is 3.1 times as high as that of MMC-solution. In clinical experiments 81 patients with carcinomatous effusions were administered with MMC-CH (2.0-2.4 mg/kg in terms of MMC) in bolus intracavitarily. Fifty-one patients responded well to the MMC-CH therapy. Nineteen patients were alive for more than 6 months. The responders showed marked improvement in subjective symptoms, and 26 patients became dischargeable from hospital. Bone marrow suppression and peritoneal irritation were main adverse effects, but the symptoms were temporary and not so serious in spite of a high dose of MMC.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3100014     DOI： 10.1002/1097-0142(19870115)59:2<245::aid-cncr2820590212>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  11 in total

1.  Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination: a prospective randomized study.

Authors:  K Sugimachi; Y Maehara; K Akazawa; Y Kondo; Y Kunii; M Kitamura; H Yamaoka; Y Takahashi; T Kito; M Katou
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  The role of monoclonal antibody A7 as a drug modifier in cancer therapy.

Authors:  K Kitamura; T Miyagaki; N Yamaoka; H Tsurumi; A Noguchi; T Yamaguchi; T Takahashi
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

3.  Treatment of malignant peritoneal effusion in digestive and ovarian cancer.

Authors:  F N Gilly; P Y Carry; A Brachet; A C Sayag; G Panteix; B Salle; J Bienvenu; V Banssillon; G Burgard; M Manchon
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

4.  Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination.

Authors:  Y Yonemura; T Fujimura; S Fushida; S Takegawa; T Kamata; K Katayama; T Kosaka; A Yamaguchi; K Miwa; I Miyazaki
Journal:  World J Surg       Date:  1991 Jul-Aug       Impact factor: 3.352

5.  Influence of intraperitoneal therapy with mitomycin C adsorbed on activated carbon on anastomotic and wound healing in rats.

Authors:  Marc Jansen; Petra Lynen Jansen; Jürgen Fass; Elke Langejürgen; Sabine Forsch; Lothar Tietze; Volker Schumpelick
Journal:  Dig Dis Sci       Date:  2002-09       Impact factor: 3.199

6.  Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles.

Authors:  T Takahashi; A Hagiwara; M Shimotsuma; K Sawai; T Yamaguchi
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

7.  Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol.

Authors:  T Kaila; L Roivas; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Primary gastric leiomyosarcoma in young revealed by a massive hematemesis.

Authors:  Mehdi Soufi; Abdelkader Errougani; Rachid M Chekkof
Journal:  J Gastrointest Cancer       Date:  2009

9.  Effect of intraperitoneal injection of mitomycin C adsorbed on activated carbon particles on induction of cytolytic peritoneal macrophages of mice.

Authors:  M Sakita; A Iwamoto; K Hata; A Hagiwara; T Takahashi
Journal:  Jpn J Cancer Res       Date:  1989-12

10.  Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer.

Authors:  K Kunieda; T Seki; S Nakatani; M Wakabayashi; T Shiro; K Inoue; M Sougawa; R Kimura; K Harada
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.